Form 4: Adam Lezack Acquires 11,247 Shares of Beta Bionics, Inc. Common Stock

Director Adam Lezack reports the acquisition of 11,247 shares of Beta Bionics, Inc. common stock through a restricted stock unit award.

Summary

• Adam Lezack, a director of Beta Bionics, Inc. (BBNX), reported a transaction on March 15, 2025.
• Lezack acquired 11,247 shares of common stock through a restricted stock unit award.
• The acquisition price was $0 per share.
• Following the transaction, Lezack directly owns 11,247 shares of Beta Bionics, Inc.
• The restricted stock unit award was granted under the Issuer's 2025 Equity Incentive Plan.

Sentiment

Score: 5

Explanation: The document is a neutral regulatory filing. The sentiment is neither positive nor negative.

Positives

• The acquisition of shares by a director could be seen as a positive signal, indicating confidence in the company's future prospects.

Industry Context

Form 4 filings are a routine part of regulatory compliance for corporate insiders and provide transparency into their transactions in the company's stock.

Stakeholder Impact

• The transaction may have a minor positive impact on shareholder sentiment due to the director's increased stake in the company.

Key Dates